VIDEO: Concerns linger for interchangeable biosimilar switch ‘without prescriber knowing’
In a Healio video exclusive, Edward V. Loftus Jr., MD, noted that although some concerns remain for switching patients between interchangeable biosimilars, data has continued to show acceptable outcomes as well as “increased access.” With three interchangeable biosimilars now available for use in patients with inflammatory bowel disease – Cyltezo (adalimumab-adbm, Boehringer